HRP20151230T1 - Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 - Google Patents
Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 Download PDFInfo
- Publication number
- HRP20151230T1 HRP20151230T1 HRP20151230TT HRP20151230T HRP20151230T1 HR P20151230 T1 HRP20151230 T1 HR P20151230T1 HR P20151230T T HRP20151230T T HR P20151230TT HR P20151230 T HRP20151230 T HR P20151230T HR P20151230 T1 HRP20151230 T1 HR P20151230T1
- Authority
- HR
- Croatia
- Prior art keywords
- metformin
- combination
- pharmaceutically acceptable
- lys6
- acceptable salt
- Prior art date
Links
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims 8
- 229960003105 metformin Drugs 0.000 title claims 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims 6
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
- 229960001093 lixisenatide Drugs 0.000 title 1
- 108010004367 lixisenatide Proteins 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 8
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 claims 6
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000011360 adjunctive therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (8)
1. Kombinacija za upotrebu za liječenje dijabetes melitusa tipa 2, naznačena time da navedena kombinacija sadrži
(a) desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegovu farmaceutski prihvatljivu sol,
(b) metformin ili/i njegovu farmaceutski prihvatljivu sol,
pri čemu je subjekt koji se tretira pretio i ima indeks tjelesne mase od najmanje 30 kg/m2 i ima starost u rasponu od 18 do 50 godina, te pri čemu dijabetes melitusa tipa 2 nije adekvatno kontroliran samo s metforminom, te gdje je desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegova farmaceutski prihvatljiva sol pripremljena za davanje jednom injekcijom dnevno.
2. Kombinacija za upotrebu prema zahtjevu 1, naznačena time da se desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegova farmaceutski prihvatljiva sol daje potkožno.
3. Kombinacija za upotrebu prema zahtjevu 1 ili 2, naznačena time da se metformin daje oralno.
4. Kombinacija za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačena time da se desPro36Exendin-4(1-39)-Lys6-NH2 ili/i farmaceutski prihvatljiva sol daje kao dodatna terapija uz davanje metformina.
5. Kombinacija za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt kojeg treba liječiti je odrasli subjekt.
6. Kombinacija za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačena time da tretman samo sa dozom od najmanje 1.5 g/dan metformina tijekom tri mjeseca ne kontrolira adekvatno dijabetes melitus tipa 2.
7. Kombinacija za upotrebu prema bilo kojem od prethodnih zahtjeva, naznačena time da subjekt kojeg treba liječiti ima vrijednost HbA1c u rasponu od 7% do 10%.
8. Upotreba kombinacije
(a) desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegove farmaceutski prihvatljive soli,
(b) metformina ili/i njegove farmaceutski prihvatljive soli,
naznačena tima da je za proizvodnju lijeka za liječenje dijabetes melitusa tipa 2, pri čemu je subjekt koji se tretira pretio i ima indeks tjelesne mase od najmanje 30 kg/m2 i ima starost u rasponu od 18 do 50 godina, te pri čemu dijabetes melitus tipa 2 nije adekvatno kontroliran samo s metforminom, te gdje je desPro36Exendin-4(1-39)-Lys6-NH2 ili/i njegova farmaceutski prihvatljiva sol pripremljena za davanje jednom injekcijom dnevno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09175876.3A EP2324853B1 (en) | 2009-11-13 | 2009-11-13 | Lixisenatide as add-on to metformin in the treatment of diabetes type 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151230T1 true HRP20151230T1 (hr) | 2015-12-18 |
Family
ID=41728467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151230TT HRP20151230T1 (hr) | 2009-11-13 | 2015-11-16 | Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2324853B1 (hr) |
| CY (1) | CY1117603T1 (hr) |
| DK (1) | DK2324853T3 (hr) |
| ES (1) | ES2553593T3 (hr) |
| HR (1) | HRP20151230T1 (hr) |
| HU (1) | HUE026489T2 (hr) |
| PL (1) | PL2324853T3 (hr) |
| PT (1) | PT2324853E (hr) |
| SI (1) | SI2324853T1 (hr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010043566A2 (de) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem insulin und einem glp-1-agonisten |
| ES2855146T3 (es) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina |
| US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
| PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
| CA2825162A1 (en) * | 2011-02-02 | 2012-08-09 | Sanofi-Aventis Deutschland Gmbh | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
| US20130040878A1 (en) * | 2011-05-13 | 2013-02-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 patients |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| BR112013029062A2 (pt) | 2011-05-13 | 2016-11-29 | Sanofi Aventis Deutschland | lixisenatida e metformina para o tratamento de diabetes tipo 2 |
| US8735349B2 (en) * | 2011-05-13 | 2014-05-27 | Sanofi-Aventis Deutschland Gmbh | Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L |
| PT2750699E (pt) | 2011-08-29 | 2015-11-03 | Sanofi Aventis Deutschland | Acelerómetro pendular |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| AR103415A1 (es) * | 2015-01-16 | 2017-05-10 | Sanofi Aventis Deutschland | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
-
2009
- 2009-11-13 EP EP09175876.3A patent/EP2324853B1/en not_active Revoked
- 2009-11-13 ES ES09175876.3T patent/ES2553593T3/es active Active
- 2009-11-13 HU HUE09175876A patent/HUE026489T2/en unknown
- 2009-11-13 PT PT91758763T patent/PT2324853E/pt unknown
- 2009-11-13 DK DK09175876.3T patent/DK2324853T3/en active
- 2009-11-13 PL PL09175876T patent/PL2324853T3/pl unknown
- 2009-11-13 SI SI200931317T patent/SI2324853T1/sl unknown
-
2015
- 2015-11-16 HR HRP20151230TT patent/HRP20151230T1/hr unknown
- 2015-11-24 CY CY20151101054T patent/CY1117603T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2324853A1 (en) | 2011-05-25 |
| CY1117603T1 (el) | 2017-04-26 |
| SI2324853T1 (sl) | 2015-12-31 |
| ES2553593T3 (es) | 2015-12-10 |
| HUE026489T2 (en) | 2016-06-28 |
| PL2324853T3 (pl) | 2016-01-29 |
| PT2324853E (pt) | 2015-11-30 |
| EP2324853B1 (en) | 2015-08-26 |
| DK2324853T3 (en) | 2015-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151230T1 (hr) | Liksisenatid kao dodatak metforminu kod lijeäśenja dijabetesa tipa 2 | |
| HRP20121029T4 (hr) | Liksisenatid kao pomoćna terapija uz inzulin glargin i metformin kod liječenja dijabetesa tip 2 | |
| HRP20150353T1 (hr) | Farmaceutski pripravak koji sadrži glp-1 agonist, inzulin i metionin | |
| HRP20131120T1 (hr) | Farmaceutski pripravak koji sadrži (1s)-1,5-anhidro-1-[5-(4-etoksibenzil)-2-metoksi-4-metilfenil]-1-tio-d-glucitol i metformin, te njegova uporaba za lijeäśenje dijabetesa | |
| HRP20161038T1 (hr) | Genz 112638 za liječenje gaucherove ili fabrijeve bolesti u kombiniranoj terapiji | |
| JP2016106150A5 (hr) | ||
| JP2009525343A5 (hr) | ||
| HRP20230470T1 (hr) | Formulacija fiksnog omjera inzulin glargin/liksisenatid | |
| HRP20151068T1 (hr) | Farmaceutska kombinacija za upotrebu za glikemijsku kontrolu kod pacijenata s dijabetesom tipa 2 | |
| HRP20110659T1 (hr) | Uporaba beta blokatora za proizvodnju lijeka za liječenje hemangioma | |
| FI2981269T3 (fi) | Aineenvaihduntahäiriöiden hoito hevoseläimillä | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| HRP20231142T3 (hr) | Kontrolirano oslobađanje 25-hidroksivitamina d | |
| EA201170018A1 (ru) | Разагилин для изменения течения болезни паркинсона | |
| JP2015517488A5 (hr) | ||
| HRP20151369T1 (hr) | Liksisenatid i metformin za lijeäśenje dijabetesa tipa 2 | |
| JP2008545703A5 (hr) | ||
| JP2017538705A5 (hr) | ||
| JP2009528985A5 (hr) | ||
| JP2013516493A5 (hr) | ||
| JP2018138596A5 (hr) | ||
| WO2008075320A3 (en) | Antilipidemic pharmaceutical compositions and process for preparation thereof | |
| JP2007119497A5 (hr) | ||
| JP2011500589A5 (hr) | ||
| NO20054381L (no) | 1,3-substituerte sykloalkylderivater med sure, som oftest heterosykliske grupper, deres fremstilling og deres anvendelse som legemiddel |